Phathom Pharmaceuticals Inc.
PHAT | NASDAQ
$7.54
+$0.09 (+1.21%)
Sep 22, 2026, 10:47 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 175.11M | 55.25M | 682K | n/a | n/a | n/a |
Cost of Revenue | 22.6M | 7.97M | 167K | 620K | 521K | 300K |
Gross Profit | 152.51M | 47.28M | 515K | -620K | -521K | -300K |
Operating Income | -159.99M | -277.47M | -167.31M | -172.44M | -135.08M | -125.67M |
Interest Income | 7.04M | 15.16M | 7.88M | 2.13M | 41K | 1.09M |
Pretax Income | -221.25M | -334.33M | -201.59M | -197.72M | -143.88M | -129.07M |
Net Income | -221.25M | -334.33M | -201.59M | -197.72M | -143.88M | -129.07M |
Selling & General & Admin | 279.72M | 290.66M | 117.93M | 100.38M | 62.22M | 27.22M |
Research & Development | 32.78M | 34.08M | 49.9M | 71.44M | 72.34M | 98.15M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 312.5M | 324.75M | 167.83M | 171.82M | 134.56M | 125.37M |
Interest Expense | 68.12M | 72.01M | 41.97M | 27.31M | 6.79M | 4.58M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 335.1M | 332.72M | 167.99M | 172.44M | 135.08M | 125.67M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 72.92M | 63.18M | 51.29M | 39.12M | 37M | 33.23M |
Shares Outstanding (Diluted) | 72.92M | 63.18M | 51.29M | 39.12M | 37M | 33.23M |
EPS (Basic) | -3.03 | -5.29 | -3.93 | -5.70 | -4 | -4.01 |
EPS (Diluted) | -3.03 | -5.29 | -3.93 | -5.70 | -4 | -4.01 |
EBITDA | -152.5M | -261.52M | -159.05M | -169.8M | -136.57M | -124.19M |
EBIT | -153.13M | -262.32M | -159.62M | -170.42M | -137.1M | -124.49M |
Depreciation & Amortization | 633K | 795K | 575K | 620K | 521K | 300K |
Add to Watchlist
Select watchlists to add or remove PHAT